Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non Operating Income: 2021-2024

Historic Other Non Operating Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $11.4 million.

  • ARS Pharmaceuticals' Other Non Operating Income fell 22.10% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 3.23%. This contributed to the annual value of $11.4 million for FY2024, which is 13.58% down from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Other Non Operating Income is $11.4 million, which was down 13.58% from $13.2 million recorded in FY2023.
  • ARS Pharmaceuticals' Other Non Operating Income's 5-year high stood at $13.2 million during FY2023, with a 5-year trough of -$789,000 in FY2021.
  • Its 3-year average for Other Non Operating Income is $8.5 million, with a median of $11.4 million in 2024.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Other Non Operating Income surged by 1,250.62% in 2023, and later dropped by 13.58% in 2024.
  • ARS Pharmaceuticals' Other Non Operating Income (Yearly) stood at -$789,000 in 2021, then soared by 223.45% to $974,000 in 2022, then skyrocketed by 1,250.62% to $13.2 million in 2023, then dropped by 13.58% to $11.4 million in 2024.